Kyverna Therapeutics, Inc. KYTX
5.23 USD +0.15 (+2.95%)
Nov 11, 2026, 12:37 PM EST
5.02 Day range 5.23
4.50 52-week range 13.67
- YTD
- -44.36%
- 1 year
- -25.29%
News
benzinga.com Kyverna Therapeutics Publishes Primary Analysis Of KYSA-8 Trial In Participants With Stiff Person Syndrome In Journal Of American Medical Association Neurology Kyverna Therapeutics, Inc. (Nasdaq: KYTX), a late-stage clinical immunology company pioneering transformative therapies for people with neurologic autoimmune diseases, today announced the publication…
globenewswire.com Kyverna Therapeutics Announces Publication of Registrational Miv-cel Data in Patients with Stiff Person Syndrome in JAMA Neurology Publication reinforces miv-cel's potential to deliver durable clinical benefit with a single dose, enabled by miv-cel's unique construct, and become the first approved therapy in SPS and first…
benzinga.com 12 Health Care Stocks Moving In Friday's Pre-Market Session Gainers Milestone Scientific (AMEX:MLSS) stock moved upwards by 19.5% to $0.36 during Friday's pre-market session. The company's market cap stands at $27.1 million. Eton Pharmaceuticals (NASDAQ:ETON)…
globenewswire.com Kyverna Therapeutics to Present at the Jefferies London Healthcare Conference EMERYVILLE, Calif., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Kyverna Therapeutics, Inc. (Nasdaq: KYTX), a late-stage clinical immunology company pioneering transformative therapies for people with…
benzinga.com Kyverna Therapeutics Presents Updated Results From Its Phase 1 Trial Of CD-19 Directed CAR T-Cell Therapy In Progressive Multiple Sclerosis At MS Toronto 2026 Kyverna Therapeutics, Inc. (NASDAQ:KYTX), a late-stage clinical immunology company pioneering transformative therapies for people with neurologic autoimmune diseases, today announced updated data…
benzinga.com Kyverna Therapeutics To Present Full One-Year Data Set From KYSA-8, Registrational Trial Of Miv-Cel In Patients With Stiff Person Syndrome, At MS Toronto 2026, Joint ACTRIMS-ECTRIMS Meeting Miv-cel reversed disability and achieved durable efficacy across all primary and secondary endpoints through one year, with nearly all patients remaining off chronic immunotherapies Deep B-cell…
benzinga.com Kyverna Therapeutics To Demonstrate Two Abstracts For Presentation At MSToronto2026 10th Joint ACTRIMS-ECTRIMS Meeting Kyverna Therapeutics, Inc. (Nasdaq: KYTX), a late-stage clinical immunology company pioneering transformative therapies for people with neurologic autoimmune diseases, today announced two abstracts…
benzinga.com Kyverna Therapeutics Therapy Delivers Sustained Relief in Rare Neurological Conditions Kyverna Therapeutics reports positive one-year clinical trial data for miv-cel in stiff person syndrome and myasthenia gravis.
benzinga.com Kyverna Therapeutics Announces One-year Topline Data From KYSA-8, Its Trial Of Miv-Cel In Patients With Stiff Person Syndrome, And Topline Longer-Term Follow-up Data From Phase 2 Of KYSA-6, Its Trial In Patients With Generalized Myasthenia Gravis; Topline Durability Data Reinforce Potential For Single-dose Miv-Cel To Free Patients From Lifelong Disease Burden And Chronic Immunotherapies, Further Highlighting Miv-Cel’s Differentiated Construct Sustained clinical benefit and reversal of disability through one year support the potential to be the first approved therapy in SPS and first approved CAR T-cell therapy for autoimmune disease;…
benzinga.com Kyverna Therapeutics Q2 EPS $(0.63) Beats $(0.68) Estimate Kyverna Therapeutics (NASDAQ:KYTX) reported quarterly losses of $(0.63) per share which beat the analyst consensus estimate of $(0.68) by 7.35 percent. This is a 35.05 percent increase over losses of…- benzinga.com Kyverna Therapeutics, ElevateBio Announce Manufacturing Agreement For Both U.S. Commercial And Global Clinical Supply Of Miv-Cel, Kyverna’s Autologous CD19-Directed CAR T-Cell Therapy Kyverna Therapeutics, Inc. (NASDAQ:KYTX), a late-stage clinical biopharmaceutical company developing cell therapies for patients with autoimmune diseases, and ElevateBio, a technology-driven advanced…
benzinga.com 12 Health Care Stocks Moving In Wednesday's Pre-Market Session 
benzinga.com Why Kyverna Therapeutics Shares Are Trading Higher By Over 25%; Here Are 20 Stocks Moving Premarket Kyverna Therapeutics Inc (NASDAQ: KYTX) shares rose 25.8% in pre-market trading after positive trial results for miv-cel. Other gainers include HCAI, ELPW, and ALP.
benzinga.com How M&A Unlocked A Biotech Rebound In 2025— And What Comes Next? Small and mid-cap biotech stocks entered 2025 like a compressed spring, and it finally snapped higher— here's why.
benzinga.com Biohaven, Omeros And Other Big Stocks Moving Lower In Friday's Pre-Market Session 
benzinga.com 12 Health Care Stocks Moving In Wednesday's Intraday Session 
benzinga.com Crude Oil Rises Over 1%; General Mills Earnings Top Views 
benzinga.com Dow Jumps 150 Points; Jabil Posts Upbeat Earnings 
benzinga.com Lennar Posts Mixed Q4 Results, Joins Worthington Enterprises And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session 
benzinga.com 12 Health Care Stocks Moving In Wednesday's Pre-Market Session 
benzinga.com Why Aditxt Shares Are Trading Higher By Around 63%; Here Are 20 Stocks Moving Premarket 
benzinga.com Lightwave Logic, Kyverna Therapeutics And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session - benzinga.com 12 Health Care Stocks Moving In Monday's After-Market Session
- benzinga.com 12 Health Care Stocks Moving In Monday's Intraday Session
benzinga.com Kyverna Therapeutics, Immunome, Almonty Industries And Other Big Stocks Moving Higher On Monday 
benzinga.com Market-Moving News for December 15th RADX: 471% | Radiopharm Theranostics' Interim Data From The First Twelve Patients In Its U.S. Phase 2b Imaging Trial Of RAD 101 In Brain Metastases Showed That 92% Of The Patients Achieved…
benzinga.com Why MindWalk Holdings Shares Are Trading Higher By Around 11%; Here Are 20 Stocks Moving Premarket 
benzinga.com Donaldson Posts Upbeat Results, Joins Science Applications International, Descartes Systems, Dollar General And Other Big Stocks Moving Higher On Thursday 
benzinga.com Palo Alto, Vizsla Silver, NetEase And Other Big Stocks Moving Lower In Thursday's Pre-Market Session 
benzinga.com FDA's Rigid Approach Adds Uncertainty To uniQure's Accelerated Pathway For Huntington's Gene Therapy William Blair notes FDA's tougher stance on gene therapy programs as AMT-130 faces uncertainty in its accelerated approval timeline.
benzinga.com 12 Health Care Stocks Moving In Tuesday's Intraday Session 
benzinga.com With Trials In Motion, Cash To 2027, Can Kyverna's Next Data Drop Turn The Stock Around? HC Wainwright upgrades Kyverna to Buy with a $5 target, citing upcoming trial data and a strong cash position that supports a runway into 2027.
benzinga.com This Commercial Metals Analyst Turns Bullish; Here Are Top 5 Upgrades For Tuesday 
benzinga.com 12 Health Care Stocks Moving In Monday's After-Market Session 
benzinga.com Why Signet Jewelers Shares Are Trading Lower By Over 12%? Here Are Other Stocks Moving In Thursday's Mid-Day Session - benzinga.com Why Clever Leaves Holdings Shares Are Trading Lower By Around 60%? Here Are Other Stocks Moving In Monday's Mid-Day Session